

IN THE CLAIMS

Please substitute the following set of claims:

1. (Original) A method for treating tumors in a mammal comprising:
administering to the mammal spores of a toxin-defective, anaerobic bacterium;
and
administering to the mammal a microtubule stabilizing anti-tumor agent; whereby
the tumor regresses or its growth is slowed or arrested.
2. (Original) The method of claim 1 wherein the anaerobic bacterium is *Clostridium novyi*.
3. (Original) The method of claim 1 wherein the anaerobic bacterium is *Clostridium sordellii*.
4. (Original) The method of claim 1 wherein the spores are administered intravenously.
5. (Original) The method of claim 1 wherein the spores are administered intratumorally.
6. (Original) The method of claim 1 wherein all or part of a toxin gene of a wild type form of the anaerobic bacterium is deleted.
7. (Original) The method of claim 1 wherein the anti-tumor agent is a taxane.
8. (Original) The method of claim 1 wherein the anti-tumor agent is selected from the group consisting of 10-deacetyltaxol; 7-epi-10-deacetyltaxol; 7-xylosyl-10-deacetyltaxol; 7-epi-taxol; cephalomannine; baccatin III; baccatin V; 10-deacetyl baccatin III; 7-epi-10-deacetyl baccatin III; 2-debenzoyl-2-(p-trifluoromethylbenzoyl)taxol; and 20-acetoxy-4-deacetyl-5-epi-20, O-secotaxol.
9. (Original) The method of claim 1 wherein the anti-tumor agent is selected from the group consisting of arsenic trioxide, discodermolide, epothilone B, and (+)-14-normethyl discodermolide.
10. (Original) The method of claim 1 wherein the anti-tumor agent is taxol.
11. (Original) The method of claim 1 wherein the anti-tumor agent is taxotere.
12. (Original) The method of claim 1 wherein the anti-tumor agent is cephalomannine.

13. (Original) The method of claim 1 further comprising:
administering a nitric oxide synthetase (NOS) inhibitor to the mammal.
14. (Original) The method of claim 1 wherein the spores and anti-tumor agent are administered serially.
15. (Original) The method of claim 13 wherein the spores, anti-tumor agent and NOS inhibitor are administered serially.
16. (Currently amended) A kit for treating tumors, wherein components of the kit are in a divided or undivided container, said components comprising:
spores of ~~an~~ a toxin-defective, anaerobic bacterium ~~which is toxin-defective;~~
~~an~~ a microtubule stabilizing, anti-tumor agent ~~which stabilizes microtubules~~.
17. (Original) The kit of claim 16 wherein all or part of a toxin gene of a wild type form of the anaerobic bacterium is deleted in the spores of the anaerobic bacterium.
18. (Original) The kit of claim 16 further comprising a nitric oxide synthetase inhibitor.
19. (Original) The kit of claim 16 wherein the anaerobic bacterium is *Clostridium novyi*.
20. (Original) The kit of claim 16 wherein the anaerobic bacterium is *Clostridium sordellii*.
21. (Currently amended) The kit of claim 16 wherein the anti-tumor agent is taxol.
22. (Currently amended) The kit of claim 16 wherein the anti-tumor agent is taxotere.
23. (Currently amended) The kit of claim 16 wherein the anti-tumor agent is cephalomannine.
24. (Currently amended) The kit of claim 16 wherein the anti-tumor agent is a taxane.